AI Analysis | Feedback

Here are a few brief analogies for Revelation Biosciences (REVB):

• It's like an early-stage biotech trying to develop the next generation of nasal therapies for colds, flu, and allergies, akin to a specialized, smaller Pfizer.

• It's also developing rapid diagnostic tests for respiratory viruses, much like an early-stage Quidel or Abbott Diagnostics.

AI Analysis | Feedback

• REVTx-99: An anti-viral nasal drop designed for the prevention or treatment of respiratory viral infections and nasal congestion due to allergies or chronic rhinosinusitis.
• REVDx-501: A rapid test kit developed to detect various respiratory viral infections.
• REVTx-200: An intranasal immunomodulator adjunct intended for use in combination with an intramuscular vaccination.

AI Analysis | Feedback

Revelation Biosciences, Inc. (REVB) is a clinical-stage biopharmaceutical company. As such, the company is primarily focused on the research, development, and clinical testing of its therapeutic and diagnostic candidates (REVTx-99, REVDx-501, REVTx-200).

At this clinical stage, Revelation Biosciences does not have major customers in the traditional sense of selling commercial products or services to other companies or individuals. Their products are still in development and have not yet received regulatory approval for commercialization.

AI Analysis | Feedback

AI Analysis | Feedback

James Rolke, Chairman and Chief Executive Officer

Mr. Rolke co-founded Revelation Biosciences and has served as its Chief Executive Officer since May 2020. He also became Chairman in June 2025. With over 30 years of experience in the biotechnology industry, he previously held various leadership roles in Research and Development at La Jolla Pharmaceutical Company from 2012 to 2020, serving as Chief Scientific Officer from 2017 to 2020. At La Jolla, he oversaw the development of multiple technologies, including 6 INDs and 2 marketing approvals for Giapreza and artesunate. Prior to that, from 2009 to 2012, Mr. Rolke was Chief Technology Officer at Pluromed, Inc., which was acquired by Sanofi, where he played a key role in the approvals of two medical devices. His earlier career included positions at Prospect Therapeutics, Inc., Mersana Therapeutics, Inc., GlycoGenesys, Inc., Surgical Sealants, Inc., GelTex, Inc., and Alpha-Beta Technology, Inc.

Chester Zygmont, III, Chief Financial Officer and Corporate Secretary

Mr. Zygmont has served as Revelation Biosciences' Chief Financial Officer since the company's inception and brings over 20 years of experience in finance. In 2016, he co-founded Jivanas, a social enterprise operating a factory in Nepal. He also co-founded oOxesis Biotechnology, LLC in 2013. From 2012 to 2016, Mr. Zygmont was the Senior Director of Finance at La Jolla Pharmaceutical Company, where he played a role in bringing the company to its Nasdaq listing. He also served as Managing Director at Z3 Capital, LLC, a privately held investment firm, and as Vice President at Symmetry Advisors, Inc., a private equity leveraged buyout firm. While at Symmetry, he managed finance and accounting for its SPAC and was instrumental in a $600 million buyout of a portfolio company.

Robin Marsden, Senior Vice President, Biology

Ms. Marsden has over 25 years of experience in biotechnology, where she has been responsible for executing bioanalytical and immunogenicity strategies supporting three FDA-approved products: Symlin and Byetta (both Astra-Zeneca), and Giapreza (La Jolla Pharmaceutical). She was previously a Senior Director at La Jolla Pharmaceutical.

Carol Odle, Vice President, Clinical Operations

Ms. Odle possesses over 30 years of clinical research experience, including extensive global clinical leadership roles at pharmaceutical companies and clinical research organizations. Before joining Revelation Biosciences, she was the Director of Clinical Projects at La Jolla Pharmaceutical Company, where she led global clinical trials, including for the FDA-approved product Giapreza.

Sandra Vedrick, Vice President of Human Resources & Investor Relations

AI Analysis | Feedback

The key risks for Revelation Biosciences (REVB), a clinical-stage biopharmaceutical company, are primarily centered around the successful development and commercialization of its product candidates, its ability to secure ongoing funding, and maintaining its listing on a major exchange.

1. Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage company with no approved products, Revelation Biosciences faces a significant risk that its lead therapeutic and diagnostic candidates, such as REVTx-99, REVDx-501, and REVTx-200, may not successfully complete clinical trials or receive the necessary regulatory approvals. Failure or delays in clinical trials, or the occurrence of unexpected adverse safety events, could have severe consequences for the company's prospects and share price. Historically, less than 12% of candidate drugs make it to market, highlighting the inherent challenges in drug development.
2. Funding and Liquidity Risk: Revelation Biosciences has a rapid cash burn rate and relies on its ability to secure additional funding to continue operations and advance its clinical programs. The company's cash position indicates a need for further financing, and past capital-raising events, often involving equity offerings and warrant structures, have frequently led to dilution for existing shareholders and negative market reactions. The company has reported significant financial losses.
3. Nasdaq Listing and Share Price Stability Risk: Revelation Biosciences has received non-compliance letters from Nasdaq regarding its minimum bid price, which threatens its listing status. The company has also undertaken multiple reverse stock splits in an attempt to regain compliance, which are often perceived by investors as a "red flag" indicating persistent issues with a low share price and concerns about long-term viability. The stock exhibits high volatility and extreme price swings.

AI Analysis | Feedback

AI Analysis | Feedback

Revelation Biosciences, Inc. (REVB) operates in several addressable markets for its key products and services. The estimated market sizes for these areas are outlined below:

REVTx-99 (anti-viral nasal drop for respiratory viral infections, nasal congestion due to allergies, or chronic rhinosinusitis)

• Respiratory Viral Infections Treatment: The global viral respiratory infections treatment market was valued at approximately USD 62.24 billion in 2024 and is projected to reach USD 119.54 billion by 2032. Another estimate places the global respiratory virus infection drugs market at USD 22.37 billion in 2023, forecasted to reach USD 48.59 billion by 2032.
• Nasal Congestion due to Allergies (Allergic Rhinitis): The global nasal allergy treatment market is expected to reach approximately US$ 19.2 billion by 2032. The global allergy rhinitis drugs market size was estimated at USD 14.58 billion in 2025 and is predicted to grow to approximately USD 21.61 billion by 2035. For nasal gels specifically, a segment relevant to nasal congestion, the global market size is projected to be around USD 15.0 billion by 2033 from USD 8.8 billion in 2023. North America held 34% of the nasal gels market share in 2023.
• Chronic Rhinosinusitis: The global chronic rhinosinusitis with nasal polyps market is projected to expand from USD 5.1 billion in 2024 to USD 7.6 billion by 2030. The U.S. market for chronic rhinosinusitis with nasal polyps is estimated at USD 1.91 billion in 2024. Intranasal therapies, a relevant administration route for REVTx-99, held the largest market share (50%) within the chronic rhinosinusitis with nasal polyps market in 2024, valued at approximately USD 2.55 billion. The global sinusitis treatment market size is expected to grow from USD 2.27 billion in 2023 to USD 3.97 billion by 2033.

REVDx-501 (rapid test kit for respiratory viral infections)

• Rapid Diagnostic Tests for Respiratory Viral Infections: The global rapid influenza diagnostic tests market was valued at USD 1.4 billion in 2024 and is expected to reach around USD 2.3 billion by 2034. North America accounted for approximately 34.5% of this market in 2024. Within the broader infectious respiratory disease diagnostics market, the rapid/point-of-care diagnostics segment is anticipated to exhibit the fastest growth. North America dominated the infectious respiratory disease diagnostics market, holding 44.62% of the revenue share in 2025. The overall point-of-care (POC) diagnostics market was US$ 36,000.4 million in 2021 and is expected to reach US$ 82,958.3 million by 2028.

REVTx-200 (intranasal immunomodulator adjunct for intramuscular vaccination)

• Intranasal Immunomodulator Adjuncts (Vaccine Adjuvants): The global vaccine adjuvants market size was estimated at USD 3.94 billion in 2025 and is projected to reach USD 5.96 billion by 2033. Another source indicates the global vaccine adjuvants market was valued at USD 3.83 billion in 2024 and is expected to reach USD 5.43 billion by 2032. North America held the largest market share in the global vaccine adjuvants market, accounting for 39.32% in 2025 and 40% in 2024. The intranasal route of administration is specifically noted as holding a remarkable revenue share within the vaccine adjuvants market in 2022. The U.S. vaccine adjuvants market was valued at USD 1.25 billion in 2024 and is expected to reach USD 1.76 billion by 2032.

AI Analysis | Feedback

1. Commercialization of the Gemini (REVTx-100/REVTx-300) Platform: The Gemini platform, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), is designed for acute and chronic inflammation-driven diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD), and post-surgical infections. Revelation Biosciences has recently announced positive results from its PRIME clinical study in late-stage CKD patients and has reached an agreement with the FDA for a single adaptive Phase 2/3 study for Gemini. The successful progression through these clinical trials and subsequent regulatory approvals for indications such as AKI, CKD, and healthcare-associated bacterial infections (via REVTx-100) are anticipated to be a significant driver of future revenue.
2. Commercialization of REVTx-99: REVTx-99 is a lead therapeutic candidate, an anti-viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for nasal congestion due to allergies or chronic rhinosinusitis. The company has shown positive in vitro anti-viral activity against SARS-CoV-2 and completed enrollment and dosing in a Phase 2b viral challenge study for H3N2 influenza. Achieving regulatory approval and market launch for these broad indications would contribute to future revenue generation.
3. Commercialization of REVDx-501: REVDx-501 is Revelation Biosciences' lead diagnostic product, described as a rapid test kit capable of detecting various respiratory viral infections without the need for specialized instrumentation. The company has engaged MedWorld Advisors to facilitate partnering for this asset. Successful partnerships and the eventual market introduction of this point-of-care diagnostic are expected to drive revenue.
4. Advancement and Commercialization of REVTx-200: REVTx-200 is an intranasal immunomodulator adjunct intended for use in combination with intramuscular vaccinations to provide more complete immunity. This product aims to improve vaccine effectiveness by eliciting both systemic and mucosal immune responses. Successful clinical development, regulatory approval, and integration into vaccination strategies could open a new revenue stream in the infectious disease prevention market.

AI Analysis | Feedback

Share Repurchases

• Revelation Biosciences, Inc. has not reported any share repurchases over the last 3-5 years.

Share Issuance

• In January 2026, Revelation Biosciences received $11 million in gross proceeds from the immediate exercise of outstanding warrants to purchase approximately 13,065,000 shares of common stock.
• The company completed a warrant inducement in January 2026, resulting in $6.7 million in net proceeds.
• Revelation Biosciences implemented multiple reverse stock splits, including a 1-for-30 reverse stock split in January 2024 and a 1-for-4 reverse stock split effective January 28, 2026, to maintain Nasdaq listing compliance.

Inbound Investments

• Revelation Biosciences received $11 million in gross proceeds from the exercise of outstanding warrants in January 2026.
• Net proceeds of $6.7 million were generated from a warrant inducement in January 2026.
• The company's cash on hand as of December 31, 2025, reflected proceeds from a May 2025 public offering and a September 2025 warrant inducement.

Outbound Investments

• No information is available regarding outbound investments made by Revelation Biosciences, Inc.

Capital Expenditures

• Capital expenditures for Revelation Biosciences were reported as $17,689 in the last 12 months as of March 2026.
• The company reported negative capital expenditures of $18,000 in Q4 2024.
• Revelation Biosciences plans a 2026 infrastructure build-out to commence a Phase 2/3 adaptive study for its Gemini program.